Quick Takeaways: Why It Matters? ECO’s licence of Vaxinano’s late‑stage sheep toxoplasmosis vaccine gives it a low‑cost, de‑risked way to add a high‑value preventative product that directly tackles a major cause of abortion and lamb losses, with peak sales estimated a...
Quick Takeaways: Why It Matters? ECO Animal Health’s EU launch of Ecovaxxin MS is a meaningful commercial milestone because it converts the company’s own R&D pipeline into a marketed product and gives it a differentiated position in poultry vaccines. With access to a market spanning mo...
Quick Takeaways: Why It Matters? The USDA’s positive safety verdict for Ecovaxxin MG significantly de‑risks US registration, validating ECO’s live‑strain platform and setting up a clear path toward a 2027 filing in a large Mycoplasma gallisepticum market.&nb...
Revenue: $5.4M Founded Year: 1982 Market Cap: 54.85M Total Employees: ~70 Headquarters: Maine, United States Stock Exchange: NASDAQ ImmuCell is an animal health company that aims towards the development, manufacturing, and marketing of scientifically-proven products that improve health and...
